An interventional study of Vine™ in Atrial Fibrillation, sponsored by Javelin Medical. Completed at 4 sites in 3 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-02-20.
Sponsored by Javelin Medical · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 205 studies in Atrial Fibrillation with a site in Belgium — 34 open to participants now, 52 under way, 1 of them phase 3. Atrial Fibrillation · Belgium.
Among the 205 studies in Atrial Fibrillation with a site in Belgium, this one is the 158th largest by enrollment of the 160 interventional ones that give a count, is one of 15 that started in 2017, is one of 102 with no phase, and was the 94th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →34 of the 205 studies in Atrial Fibrillation with a site in Belgium are open now. Recruiting first, the newest first:
Hospital Universitari Vall d'Hebron Research Institute · Sites in Belgium, Germany, Italy and 3 more countries
Ages 18+
AZ Sint-Jan AV · Sites in Belgium
Ages 18–80
Bayer · Sites in Belgium, United States, Bulgaria and 5 more countries
Ages 18–85
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Ages 18+
Oslo University Hospital · Sites in Belgium, United States, France and 7 more countries
Ages 18+
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
205 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 15 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 25 is below the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 296 across the 160 interventional studies, 540 across the 45 observational. Of the 138 that completed or were terminated, 63 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
122 of 205 have an industry lead sponsor. The 10 most frequent:
Javelin Medical is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Javelin Medical has 3 studies filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
17 of the studies in Atrial Fibrillation with a site in Belgium that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT07429214Biosense Webster, Inc.A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE Pro Software in Participants With PAF or PsAF | 2026-12-30 |
| NCT07428564Biosense Webster, Inc.A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE PRO Software in Participants With PsAF | 2026-12-30 |
| NCT06106594Abbott Medical DevicesVOLT CE Mark Study | 2027-01 |
| NCT07187115Boston Scientific CorporationA Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation | 2027-01 |
Add all 17 to your calendar (.ics) → With an account.
Among the 205 studies in Atrial Fibrillation with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Vine™ is a permanent carotid filter designed to provide protection against embolic stroke in people with atrial fibrillation. It is implanted bilaterally in the common carotid arteries from a thin needle under ultrasound guidance. The procedure is performed without general anesthesia and takes minutes. The safety, feasibility and tolerability of Vine™ will be evaluated. Patients who are eligible will receive Vine™ and will be followed-up for a year after device implantation.
CAPTURE is a prospective, single-arm, multicenter trial, designed to evaluate the safety, feasibility and tolerability of the Vine™ permanent carotid filter. The trial will enroll up to 30 patients, and will be conducted in up to five sites worldwide. All enrolled patients will be invited for non-invasive follow-up tests and clinical evaluations according to the study protocol.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vine™ is a permanent carotid filter made from a single nitinol wire. It is configured to capture emboli exceeding 1.2mm in size, which originate in the heart and large arteries below the neck. Vine™ has a helical structure, with leading and supporting coils interposed by a filter section.
Device: Vine™
The Vine™ is made of a super-elastic nitinol wire comprises a helix that resides within the CCA lumen and a linear stem that traverses the CCA wall. The helix includes three segments: supporting coils, filter, and leading coils. The device is available in sizes of 6.0mm - 10.0mm (in 0.5mm intervals) to accommodate individual CCA diameters
Number of patients with no incidence of device and/or procedure related Major Adverse Events (MAEs)
Major Adverse Events (MAEs) are defined as: * Death * Major and minor strokes * Major bleeding * Common carotid artery (CCA) stenosis \> 70% * Vine™ migration * CCA thrombus * Any complications in the CCA requiring endovascular treatment or surgery
Time frame: 30 days from implantation procedure
Number of patients with Procedure Success
Procedure Success is defined as Proper Vine™ Position in each CCA Proper Vine™ Position is defined as: * Supporting coil in contact with artery walls * No migration * No fracture * No Vine™ coils or portions thereof visible outside the arterial lumen * No entangled or overlapping coils
Time frame: 30 days from implantation procedure
Number of patients with no incidence of device and/or procedure related Major Adverse Events (MAEs)
Death * Major and minor strokes * Major bleeding * Common carotid artery (CCA) stenosis \> 70% * Vine™ migration * CCA thrombus * Any complications in the CCA requiring endovascular treatment or surgery
Time frame: within 3, 6, months,1, 2, 3, 4 and 5 years of implantation procedure
Number of Successful Delivery and Deployment Attempts
Successful Delivery and Deployment Attempts is defined as Proper Vine™ Position
Time frame: within 4 hours of implantation procedure
Number of patients with properly positioned Vine™ in each CCA
Proper implant position
Time frame: within 3, 6, months,1, 2, 3, 4 and 5 years of implantation procedure
Plan to share: No
Ran from Sep 2017 to primary completion in Dec 2018, 15 months.
Of 255 industry-sponsored interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 36. This study's 15 months is below that.
Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Javelin Medical